🇺🇸 FDA
Patent

US 11268096

Compounds for modulating Fc-epsilon-RI-beta expression and uses thereof

granted A61KA61K31/7088A61P

Quick answer

US patent 11268096 (Compounds for modulating Fc-epsilon-RI-beta expression and uses thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/7088, A61P, A61P29/00